

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
POMPEJUS et al.)	Art Unit: TO BE ASSIGNED
)	
Serial No. TO BE ASSIGNED)	Examiner: TO BE ASSIGNED
)	
Filed: WITH DIVISIONAL APPLICATION)	
)	
For: GENES OF BIOSYNTHESIS FROM ASHBYA GOSSYPII AND THE USE THEREOF IN MICROBIAL RIBOFLAVIN SYNTHESIS		

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT
UNDER 37 CFR §1.115

Sir:

This is a Divisional Application of Application Serial No. 09/212,247, filed on
December 16, 1998.

The above identified Divisional Application is drawn to non-elected subject
matter which was canceled from the claims during the prosecution of the parent
application. Kindly amend the Divisional Application for further prosecution as follows.

CLEAN VERSION OF AMENDMENTS

IN THE CLAIMS

Please cancel claims 2-3 and 5-29.

Please amend claims 1 and 4 to read as follows:

1. (amended) An isolated or purified protein having the polypeptide sequence depicted in SEQ ID NO:2 or a polypeptide sequence obtainable from SEQ ID NO:2 by substitution, insertion or deletion of up to 15% of the amino acids, and having the enzymatic activity of a phosphoribosyl-pyrophosphate synthetase.

4. (amended) A protein whose sequence differs from that set forth in SEQ ID NO:2 in that one or more of the following amino acid substitutions are present: lysine at position 7 replaced by valine, aspartate at position 52 replaced by histidine, leucine at position 133 replaced by isoleucine, aspartate at position 186 replaced by histidine, alanine at position 193 replaced by valine, or histidine at position 196 replaced by glutamine, wherein said protein has the activity of a phosphoribosyl-pyrophosphate synthetase.

REMARKS

The present divisional application is drawn to Group I as defined in the office action of March 29, 2000, designated as paper number 10, in the parent prosecution. Applicants have amended the claims to mirror those finally allowed in the parent, and submit that they are in condition for allowance. In view of this, applicants respectfully solicit passage of the application to issue.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,
KEIL & WEINKAUF



David C. Liechty
Reg. No. 48,692

1101 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100

DCL/kas

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

Please cancel claims 2-3 and 5-29.

Please amend claims 1 and 4 to read as follows:

1. (amended) [A] An isolated or purified protein having the polypeptide sequence depicted in SEQ ID NO:2 or a polypeptide sequence obtainable from SEQ ID NO:2 by substitution, insertion or deletion of up to 15% of the amino acids, and having the enzymatic activity of a phosphoribosyl-pyrophosphate synthetase.

4. (amended) A protein [as claimed in claim 1, in which] whose sequence differs from that set forth in SEQ ID NO:2 in that one or more of the following amino acid substitutions are present: lysine at position 7 replaced by valine, aspartate at position 52 replaced by histidine, leucine at position 133 replaced by isoleucine, aspartate at position 186 replaced by histidine, alanine at position 193 replaced by valine, or histidine at position 196 replaced by glutamine, wherein said protein has the activity of a phosphoribosyl-pyrophosphate synthetase.

COPY OF ALL CLAIMS

1. (amended) An isolated or purified protein having the polypeptide sequence depicted in SEQ ID NO:2 or a polypeptide sequence obtainable from SEQ ID NO:2 by substitution, insertion or deletion of up to 15% of the amino acids, and having the enzymatic activity of a phosphoribosyl-pyrophosphate synthetase.

4. (amended) A protein whose sequence differs from that set forth in SEQ ID NO:2 in that one or more of the following amino acid substitutions are present: lysine at position 7 replaced by valine, aspartate at position 52 replaced by histidine, leucine at position 133 replaced by isoleucine, aspartate at position 186 replaced by histidine, alanine at position 193 replaced by valine, or histidine at position 196 replaced by glutamine, wherein said protein has the activity of a phosphoribosyl-pyrophosphate synthetase.

2025-01-20 10:00:00